Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan/HCTZ vs Telmisartan in Hypertension Non-responders
NCT00144222Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2005
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Telmisartan/HCTZ with Telmisartan (2 arms). Primary endpoint: Change in mean seated trough Diastolic Blood Pressure at 8 weeks. Started Jan 2005; status: completed.
02
Drugs
telmisartanhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00144222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144222.